• Home
  • CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.

CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients.

Author List
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, Kovacs JA
Publication
The Journal of infectious diseases
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1463521
Publication Year
2008
PubMed ID
18684102
Publication Title
Read SW, Lempicki RA, Di Mascio M, Srinivasula S, Burke R, Sachau W, Bosche M, Adelsberger JW, Sereti I, Davey RT, Tavel JA, Huang CY, Issaq HJ, Fox SD, Lane H, Kovacs JA. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis. 2008 Sep 15; 198(6):843-50.